CDK12抑制介导DNA损伤并与索拉非尼协同治疗肝细胞癌
本研究通过CRISPR全激酶功能缺失筛选发现CDK12是多数肝细胞癌细胞存活的关键基因,用shRNA或共价小分子抑制剂THZ531抑制CDK12可强烈抑制细胞增殖。THZ531优先抑制DNA修复相关基因表达并诱导DNA损伤应答,与索拉非尼联用通过诱导凋亡或衰老产生显著协同效应,提示CDK12是肝细胞癌潜在药物靶点及联合治疗策略。
要点
- CDK12是多数肝细胞癌细胞系存活所必需的关键激酶。
- THZ531抑制CDK12可抑制DNA修复基因并诱导DNA损伤应答。
- THZ531与索拉非尼联用通过凋亡或衰老产生显著协同作用。
核心结论
- CDK12是肝细胞癌的潜在药物靶点,THZ531与索拉非尼联用有望成为该难治肿瘤的联合治疗方案。
研究设计与样本
- 研究采用靶向全部已知人类激酶的CRISPR功能缺失遗传筛选鉴定肝细胞癌细胞脆弱性,并结合RNA-Seq、生物信息学分析及多项体外和体内实验验证。
主要发现
- CDK12被鉴定为多数肝细胞癌细胞系的关键必需基因。
- 用shRNA或共价小分子抑制剂THZ531抑制CDK12可强烈抑制肝细胞癌细胞增殖。
- THZ531优先抑制DNA修复相关基因表达并在肝细胞癌细胞中诱导强烈DNA损伤应答。
- THZ531与索拉非尼联用通过诱导凋亡或衰老在肝细胞癌细胞中产生显著协同效应。
- 协同效应可能源于THZ531削弱索拉非尼诱导的肝细胞癌细胞适应性反应。
临床怎么用
- CDK12可作为肝细胞癌的候选药物靶点,THZ531与索拉非尼联合方案值得进一步临床转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hepatocellular carcinoma (HCC) is one of the most frequent malignancies and a major leading cause of cancer-related deaths worldwide. Several therapeutic options like sorafenib and regorafenib provide only modest survival benefit to patients with HCC. This study aims to identify novel druggable candidate genes for patients with HCC. DESIGN: A non-biased CRISPR (clustered regularly interspaced short palindromic repeats) loss-of-function genetic screen targeting all known human kinases was performed to identify vulnerabilities of HCC cells. Whole-transcriptome sequencing (RNA-Seq) and bioinformatics analyses were performed to explore the mechanisms of the action of a cyclin-dependent kinase 12 (CDK12) inhibitor in HCC cells. Multiple in vitro and in vivo assays were used to study the synergistic effects of the combination of CDK12 inhibition and sorafenib. RESULTS: We identify CDK12 as critically required for most HCC cell lines. Suppression of CDK12 using short hairpin RNAs (shRNAs) or its inhibition by the covalent small molecule inhibitor THZ531 leads to robust proliferation inhibition. THZ531 preferentially suppresses the expression of DNA repair-related genes and induces strong DNA damage response in HCC cell lines. The combination of THZ531 and sorafenib shows striking synergy by inducing apoptosis or senescence in HCC cells. The synergy between THZ531 and sorafenib may derive from the notion that THZ531 impairs the adaptive responses of HCC cells induced by sorafenib treatment. CONCLUSION: Our data highlight the potential of CDK12 as a drug target for patients with HCC. The striking synergy of THZ531 and sorafenib suggests a potential combination therapy for this difficult to treat cancer.
引用
- Wang C, Wang H, Lieftink C, et al. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut. 2019. PMID: 31519701. doi:10.1136/gutjnl-2019-318506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。